What are the information needs of parents caring for a child with Glutaric aciduria type 1?

Hilary Piercy1, Mildrid Yeo2, Sufin Yap3

  • 1Sheffield Hallam University, Sheffield, UK. h.piercy@shu.ac.uk.

BMC Pediatrics
|October 15, 2019
PubMed

Insights

Parents of children with Glutaric aciduria type 1 need specific information and support to manage the condition effectively. Addressing these needs is crucial for protecting children from metabolic harm and improving neurological outcomes.

Area of Science:

  • Metabolic disorders
  • Genetics
  • Pediatric neurology

Background:

  • Newborn screening enables early diagnosis of Glutaric aciduria type 1, offering potential for improved neurological outcomes.
  • Effective management by parents, including dietary adherence and crisis response, is vital for affected children.
  • The specific information and support requirements for parents managing Glutaric aciduria type 1 are not well understood.

Purpose of the Study:

  • To explore the information and support needs of parents managing Glutaric aciduria type 1 in their children.
  • To understand how parents access and utilize information for condition management.

Main Methods:

  • A focus group methodology was employed with five parents.
  • Discussions were guided by a topic guide, audio-recorded, and transcribed.
  • Thematic analysis was used for data analysis, involving two researchers for rigor.

Main Results:

  • Parents require a deep understanding of the condition's complexity and potential severe outcomes.
  • Parents need to actively manage the condition, coordinate care, and be involved partners in medical decisions to feel in control.

Conclusions:

  • Parents' informational needs, both initial and ongoing, are critical for their role in preventing metabolic harm.
  • Supporting parents is essential for optimizing neurological outcomes in children with Glutaric aciduria type 1.
Abstract

Related Concept Videos

Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
673
Glucose Transporters01:27

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
27.1K
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
757
Overview of Carbohydrate Metabolism01:19

Overview of Carbohydrate Metabolism

Carbohydrate metabolism is a fundamental biochemical process that ensures a constant supply of energy to living cells. The most important carbohydrate is glucose, which can be broken down via glycolysis to enter into the Krebs cycle and eventually lead to the production of ATP through oxidative phosphorylation.
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...
3.1K
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
163
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
210